Pfizer CEO Albert Bourla and CFO David Denton reaffirmed their commitment to the company's 6.5% dividend yield on May 7, 2026. The company's Q1 earnings report on May 5 surpassed analyst expectations for both revenue and profit.
Management cited improved cash flow visibility following a patent settlement for the drug Vyndamax. A favorable court ruling in Belgium regarding COVID-19 vaccine contracts further supported the financial outlook.
Non-COVID product revenues showed solid growth during the quarter. Bourla also stated the company is not currently planning any large-scale mergers that could threaten the dividend policy.
These developments have addressed investor concerns regarding the sustainability of the payout. The combination of strong results and direct communication appears to have silenced skeptics who viewed the stock as a potential yield trap.